The Scripps Research Institute Enters Major Five-Year $100 Million Collaboration with Pfizer
Advertisement
The Scripps Research Institute announced it has entered into a five year research collaboration with Pfizer Global Research and Development to advance scientific knowledge of uncured diseases and novel ways to treat them, making full use of emerging technologies and resident talent from both organizations. Under the terms of the agreement, Pfizer will pay Scripps Research $100 million over a five year period, during which scientists from Pfizer and the Institute will work together to identify and perform specific projects of mutual interest.
They will jointly study and evaluate therapeutic approaches for diseases such as cancer, diabetes, and mental illnesses. They will develop new tests to rapidly validate these new therapies for potential development as possible novel treatment options that can gain regulatory approval for use in patients.
The company will pay the Institute milestones and royalties on therapeutic compounds created through the collaboration. In addition, Pfizer will have the first right to license many discoveries made at Scripps Research during the agreement.
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Cancer drug works against viruses
Impact of prion proteins on the nerves revealed for the first time - 30-year-old research question finally answered

Cameras | Cameras | Hamamatsu Photonics

Nanoparticles: Acidic alert

Healthy cells can impact tumour progression during embryonic development - Avian embryo model of neuroblastoma

LAUDA founds subsidiary in Italy
GenOway and Boehringer Ingelheim reinforce their collaboration

Advanced dosimetry phantoms improving radiotherapy verification

Detection of cancer from exhaled breath - Breath gas analysis for medical diagnostics
Dry eye syndrome: Neuroptis successfully completes the pre-clinical phase for ML7 - Neuroptis is looking to establish industrial and financial partnerships to commence human trials
TxCell receives Fast Track Designation from FDA for Ovasave - TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease
